TS23
Phase 2Small molecule
TS23 is one of 65 small molecule programs targeting Pulmonary Embolism. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Reminyl
WWim Janssens
Phase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Intravenous Thrombolysis
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Rhtnk-Tpa
CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Phase 3
PPA Intervention
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
SP-8203
SShin Poong Pharmaceutical Co. Ltd.
Phase 3
Y-6
BBeijing Tiantan Hospital
Phase 3
Proamatine
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TS23. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTranslational Sciences, Inc.